BioSpace News Archive

VBL Therapeutics Announces Proposed Public Offering of 2.5 Million Shares of Ordinary Shares

The company ntends to use the cash from the offering for the advancement of clinical programs, product development, and for working capital and other general corporate purposes.

November 17, 2017
·
5 min read
Business

Ascendis Pharma Reports Third Quarter 2017 Financial Results

For the third quarter, Ascendis reported a net loss of €33.9 million, or €1.04 per share (basic and diluted) compared to a net loss of €18.3 million, or €0.72 per share (basic and diluted) for the same period in 2016.

November 17, 2017
·
8 min read
Biotech Beach

Sentia Medical Sciences Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases

The new initiative will firstly prioritize gastrointestinal (GI) diseases and endocrine disorders.

November 17, 2017
·
2 min read
Genetown

ReWalk Robotics Announces Pricing of Follow-on Public Offering of Ordinary Shares

All of the ordinary shares in the offering are to be sold by ReWalk.

November 17, 2017
·
5 min read
BioMidwest

Monsanto on Track to Become Carbon Neutral, Demonstrates Environmental Benefits of Modern Agriculture

Monsanto has already reduced its carbon footprint by more than 200,000 metric tons, a reduction that is roughly equal to burning 200 million pounds less coal.

November 17, 2017
·
6 min read
Business

ICON Announces Appointment of Ms. Joan Garahy to Board of Directors

November 17, 2017
·
3 min read
Business

Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director and Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire From the Board

The Company further announces that current Non-Executive Directors, Matthew Hammond and Daniel Hegglin, will retire from the Board effective today, following the successful completion of the Company’s recent financing.

November 17, 2017
·
3 min read
Pharm Country

Acorda Announces Royalty Monetization Transactions for $53M

In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on FAMPYRA payable by Biogen, up to an agreed upon threshold of royalties.

November 17, 2017
·
5 min read